TERT与DNMT1表达预测胶质瘤对地西他滨的敏感性
本研究在患者来源的IDH1突变型和野生型胶质瘤细胞系中操控TERT和DNMT1表达,评估地西他滨(DAC)单用或联合端粒酶抑制剂的抗增殖效应。结果显示,1p/19q杂合性共缺失的IDH1突变型胶质瘤肿瘤球对DAC特别敏感,DAC通过p21诱导下调TERT,且TERT和DNMT1水平可能是DAC疗效的潜在决定因素。
要点
- 1p/19q共缺失的IDH1突变型胶质瘤肿瘤球对地西他滨特别敏感。
- 地西他滨通过诱导p21下调TERT表达。
- TERT和DNMT1水平可能是地西他滨疗效的潜在决定因素。
核心结论
- 地西他滨通过p21诱导下调TERT,TERT和DNMT1水平可能是地西他滨疗效的潜在决定因素。
研究设计与样本
- 在患者来源的IDH1突变型和野生型胶质瘤细胞系中操控TERT和DNMT1表达,并用DAC单用或联合端粒酶抑制剂处理评估细胞增殖。
- 进行了RNA测序、KEGG富集和相关性分析。
主要发现
- 1p/19q杂合性共缺失的IDH1突变型胶质瘤肿瘤球对DAC特别敏感,并显示DNA复制基因显著抑制。
- 转录组分析显示DAC诱导CDKN1A/p21表达并下调TERT,多柔比星处理也观察到类似变化。
- 敲低p21导致TERT上调;TERT过表达通过非端粒酶依赖机制增加DNMT1水平和DAC敏感性。
- 靶向DNMT1的RNAi在TERT功能正常的胶质瘤细胞中消除了DAC反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Decitabine (DAC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor that is used in the treatment of patients with myelodysplastic syndromes. Previously, we showed that DAC marks antitumor activity against gliomas with isocitrate dehydrogenase 1 (IDH1) mutations. Based on promising preclinical results, a clinical trial has been launched to determine the effect of DAC in IDH-mutant gliomas. The next step is to comprehensively assess the efficacy and potential determinants of response to DAC in malignant gliomas. METHODS: The expression and activity of telomerase reverse transcriptase (TERT) and DNMT1 were manipulated in patient-derived IDH1-mutant and -wildtype glioma lines, followed by assessment of cell proliferation with DAC treatment alone or in combination with telomerase inhibitors. RNA sequencing, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and correlation analysis were performed. RESULTS: IDH1-mutant glioma tumorspheres with hemizygous codeletion of chromosome arms 1p/19q were particularly sensitive to DAC and showed significant inhibition of DNA replication genes. Our transcriptome analysis revealed that DAC induced expression of cyclin-dependent kinase inhibitor 1A/p21 (CDKN1A), along with downregulation of TERT. These molecular changes were also observed following doxorubicin treatment, supporting the importance of DAC-induced DNA damage in contributing to this effect. We demonstrated that knockdown of p21 led to TERT upregulation. Strikingly, TERT overexpression increased DNMT1 levels and DAC sensitivity via a telomerase-independent mechanism. Furthermore, RNA inhibition (RNAi) targeting of DNMT1 abrogated DAC response in TERT-proficient glioma cells. CONCLUSIONS: DAC downregulates TERT through p21 induction. Our data point to TERT and DNMT1 levels as potential determinants of response to DAC treatment.
引用
- Park JW, Sahm F, Steffl B, et al. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol. 2021. PMID: 32882013. doi:10.1093/neuonc/noaa207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。